Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1

Interventions

Gemcitabine 153Oxaliplatin 124Fluorouracil 108Capecitabine 105pembrolizumab 92Bevacizumab 79Leucovorin 76Irinotecan 72Nivolumab 70130-nm albumin-bound paclitaxel 68Paclitaxel 62Cisplatin 62Cetuximab 60Cyclophosphamide 47Albumin-Bound Paclitaxel 45Radiotherapy 39Docetaxel 36durvalumab 33Sorafenib 32Taxes 29Carboplatin 27fludarabine 26tislelizumab 25Drug Therapy 25atezolizumab 23Folfox protocol 23regorafenib 20lenvatinib 19Ipilimumab 19sintilimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × pirfenidone × Gastrointestinal × Clear all
NCT06484153 2024-07-03

Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1/2 Not yet recruiting
25 enrolled
Gastrointestinal

To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡